Literature DB >> 19853616

In vitro dynamic visualization analysis of fluorescently labeled minor capsid protein IX and core protein V by simultaneous detection.

Hideyo Ugai1, Minghui Wang, Long P Le, David A Matthews, Masato Yamamoto, David T Curiel.   

Abstract

Oncolytic adenoviruses represent a promising therapeutic medicine for human cancer therapy, but successful translation into human clinical trials requires careful evaluation of their viral characteristics. While the function of adenovirus proteins has been analyzed in detail, the dynamics of adenovirus infection remain largely unknown due to technological constraints that prevent adequate tracking of adenovirus particles after infection. Fluorescence labeling of adenoviral particles is one new strategy designed to directly analyze the dynamic processes of viral infection in virus-host cell interactions. We hypothesized that the double labeling of an adenovirus with fluorescent proteins would allow us to properly analyze intracellular viruses and the fate of viral proteins in a live analysis of an adenovirus as compared to single labeling. Thus, we generated a fluorescently labeled adenovirus with both a red fluorescent minor capsid protein IX (pIX) [pIX monomeric red fluorescent protein 1 (mRFP1)] and a green fluorescent minor core protein V (pV) [pV enhanced green fluorescent protein (EGFP)], resulting in Ad5-IX-mRFP1-E3-V-EGFP. The fluorescent signals for pIX-mRFP1 and pV-EGFP were detected within 10 min in living cells. However, a growth curve analysis of Ad5-IX-mRFP1-E3-V-EGFP showed an approximately 150-fold reduced production of the viral progeny at 48 h postinfection as compared to adenovirus type 5. Interestingly, pIX-mRFP1 and pV-EGFP were initially localized in the cytoplasm and nucleolus, respectively, at 18 h postinfection. These proteins were observed in the nucleus during the late stage of infection, and relocalization of the proteins was observed in an adenoviral-replication-dependent manner. These results indicate that simultaneous detection of adenoviruses using dual-fluorescent proteins is suitable for real-time analysis, including identification of infected cells and monitoring of viral spread, which will be required for a complete evaluation of oncolytic adenoviruses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19853616      PMCID: PMC2787850          DOI: 10.1016/j.jmb.2009.10.034

Source DB:  PubMed          Journal:  J Mol Biol        ISSN: 0022-2836            Impact factor:   5.469


  70 in total

1.  Substrate specificity of adenovirus protease.

Authors:  Angelique Ruzindana-Umunyana; Lise Imbeault; Joseph M Weber
Journal:  Virus Res       Date:  2002-10       Impact factor: 3.303

Review 2.  A guide to choosing fluorescent proteins.

Authors:  Nathan C Shaner; Paul A Steinbach; Roger Y Tsien
Journal:  Nat Methods       Date:  2005-12       Impact factor: 28.547

Review 3.  Recent progress in the battle between oncolytic viruses and tumours.

Authors:  Kelley A Parato; Donna Senger; Peter A J Forsyth; John C Bell
Journal:  Nat Rev Cancer       Date:  2005-12       Impact factor: 60.716

Review 4.  The adenovirus capsid: major progress in minor proteins.

Authors:  Jort Vellinga; Stephanie Van der Heijdt; Rob C Hoeben
Journal:  J Gen Virol       Date:  2005-06       Impact factor: 3.891

5.  Quantitation of adenovirus type 5 empty capsids.

Authors:  Eddie Takahashi; Steven L Cohen; P K Tsai; Joyce A Sweeney
Journal:  Anal Biochem       Date:  2005-11-28       Impact factor: 3.365

6.  Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein.

Authors:  Long P Le; Jing Li; Vladimir V Ternovoi; Gene P Siegal; David T Curiel
Journal:  J Gen Virol       Date:  2005-12       Impact factor: 3.891

Review 7.  Oncolytic viruses.

Authors:  E Antonio Chiocca
Journal:  Nat Rev Cancer       Date:  2002-12       Impact factor: 60.716

8.  Dynamic monitoring of oncolytic adenovirus in vivo by genetic capsid labeling.

Authors:  Long P Le; Helen N Le; Igor P Dmitriev; Julia G Davydova; Tatyana Gavrikova; Seiji Yamamoto; David T Curiel; Masato Yamamoto
Journal:  J Natl Cancer Inst       Date:  2006-02-01       Impact factor: 13.506

9.  The adenovirus e3 promoter is sensitive to activation signals in human T cells.

Authors:  Jeffrey A Mahr; Jeremy M Boss; Linda R Gooding
Journal:  J Virol       Date:  2003-01       Impact factor: 5.103

10.  Adenovirus triggers macropinocytosis and endosomal leakage together with its clathrin-mediated uptake.

Authors:  Oliver Meier; Karin Boucke; Silvija Vig Hammer; Stephan Keller; Robert P Stidwill; Silvio Hemmi; Urs F Greber
Journal:  J Cell Biol       Date:  2002-09-09       Impact factor: 10.539

View more
  9 in total

1.  Stepwise loss of fluorescent core protein V from human adenovirus during entry into cells.

Authors:  Daniel Puntener; Martin F Engelke; Zsolt Ruzsics; Sten Strunze; Corinne Wilhelm; Urs F Greber
Journal:  J Virol       Date:  2010-11-03       Impact factor: 5.103

2.  Isolation and characterization of the DNA and protein binding activities of adenovirus core protein V.

Authors:  Jimena Pérez-Vargas; Robert C Vaughan; Carolyn Houser; Kathryn M Hastie; C Cheng Kao; Glen R Nemerow
Journal:  J Virol       Date:  2014-06-04       Impact factor: 5.103

3.  Long-term correction of hemophilia B using adenoviral delivery of CRISPR/Cas9.

Authors:  Calvin J Stephens; Elvin J Lauron; Elena Kashentseva; Zhi Hong Lu; Wayne M Yokoyama; David T Curiel
Journal:  J Control Release       Date:  2019-02-13       Impact factor: 9.776

4.  Adenoviral protein V promotes a process of viral assembly through nucleophosmin 1.

Authors:  Hideyo Ugai; George C Dobbins; Minghui Wang; Long P Le; David A Matthews; David T Curiel
Journal:  Virology       Date:  2012-06-18       Impact factor: 3.616

5.  Species D human adenovirus type 9 exhibits better virus-spread ability for antitumor efficacy among alternative serotypes.

Authors:  Junji Uchino; David T Curiel; Hideyo Ugai
Journal:  PLoS One       Date:  2014-02-04       Impact factor: 3.240

6.  A Multi Targeting Conditionally Replicating Adenovirus Displays Enhanced Oncolysis while Maintaining Expression of Immunotherapeutic Agents.

Authors:  G Clement Dobbins; Hideyo Ugai; David T Curiel; G Yancey Gillespie
Journal:  PLoS One       Date:  2015-12-21       Impact factor: 3.240

7.  A novel capsid-modified oncolytic recombinant adenovirus type 5 for tumor-targeting gene therapy by intravenous route.

Authors:  Zhen Wang; Bin Yu; Baoming Wang; Jingyi Yan; Xiao Feng; Zixuan Wang; Lizheng Wang; Haihong Zhang; Hui Wu; Jiaxin Wu; Wei Kong; Xianghui Yu
Journal:  Oncotarget       Date:  2016-07-26

8.  Derivation of a triple mosaic adenovirus for cancer gene therapy.

Authors:  Yizhe Tang; Hongju Wu; Hideyo Ugai; Qiana L Matthews; David T Curiel
Journal:  PLoS One       Date:  2009-12-31       Impact factor: 3.240

9.  Evaluation of adenovirus capsid labeling versus transgene expression.

Authors:  Jing Li; Aiman Fatima; Svetlana Komarova; Hideyo Ugai; Priyanka Uprety; Justin C Roth; Minghui Wang; Robert A Oster; David T Curiel; Qiana L Matthews
Journal:  Virol J       Date:  2010-01-26       Impact factor: 4.099

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.